RESUMEN
The authors present a case of tuberculosis of the breast as the AIDS--defining illness in a male adult patient, with CD4 counts still moderately low (475 cells/mm3) and without evidence of tuberculosis in any other organ. Literature review emphasizes the rarity of the isolated infection of the breast, especially in males, with no increase in the number of cases of this infection site even in patients with AIDS.
Asunto(s)
Infecciones Oportunistas Relacionadas con el SIDA/diagnóstico , Mastitis/diagnóstico , Tuberculosis/diagnóstico , Infecciones Oportunistas Relacionadas con el SIDA/tratamiento farmacológico , Adulto , Humanos , Masculino , Mastitis/tratamiento farmacológico , Mastitis/microbiología , Tuberculosis/tratamiento farmacológicoRESUMEN
The authors treated with paromomycin 25 patients, with AIDS and cryptosporidiosis. The drug was given orally in a doses of 500 mg qid, for a period of 14 days. Tolerance was good, with just two cases of mild side-effects. Clinical improvement was obtained in 19 (76%) patients. Parasitological cure, however, occurred only in a low percentage (25%). In some cases where initial success was observed, recrudescence occurred after some weeks or few months, but with retreatment again clinical improvement was obtained. Even if it does not lead to frequent parasite eradication, the good clinical results and tolerance permit us to consider paromomycin one of the few drugs effective for the treatment of cryptosporidial diarrhea in AIDS patients. Studies with maintainance therapy are indicated.
Asunto(s)
Infecciones Oportunistas Relacionadas con el SIDA/tratamiento farmacológico , Antibacterianos/uso terapéutico , Criptosporidiosis/tratamiento farmacológico , VIH-1 , Paromomicina/uso terapéutico , Adulto , Antibacterianos/efectos adversos , Diarrea/tratamiento farmacológico , Evaluación de Medicamentos , Femenino , Humanos , Masculino , Paromomicina/efectos adversos , RecurrenciaRESUMEN
Forty-nine American Trypanosomiasis (Chagas' disease) patients, with xenodiagnosis proven parasitemia were treated by the authors. Forty-one of these patients were given benznidazole, at dosages ranging from 5mg/kg/day to 8mg/kg/day, during a pre-established period of 60 days. In this group, 17 patients had an undetermined form of the disease, whereas 22 had cardiologic disease and 4 had digestive disease (two patients had a mixed form of the disease). Side effects were frequent, and led to the discontinuation of treatment in 17 patients. The follow-up period ranged from 1 to 20 years (mean follow-up period of 6 yrs. 7 mo). 26 (63.4%) of the patients became parasitemia-negative. The other eight patients were treated with nifurtimox, during 120 days, following a variable dose regime of 5mg/kg/day (initial dose) to 17 mg/kg/day (final dose). Six of them had severe side effects, and only one patient remained parasitemia-negative throughout the observation period (ranging from 1 to 18 years). Benznidazole proved to be better tolerated and more effective in the management of parasitemia when compared to nifurtimox, although more effective and less toxic drugs are still desirable.
Asunto(s)
Enfermedad de Chagas/tratamiento farmacológico , Nifurtimox/uso terapéutico , Nitroimidazoles/uso terapéutico , Tripanocidas/uso terapéutico , Trypanosoma cruzi , Adulto , Factores de Edad , Animales , Enfermedad de Chagas/etiología , Enfermedad Crónica , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Nifurtimox/administración & dosificación , Nitroimidazoles/administración & dosificación , Nitroimidazoles/farmacología , Factores Sexuales , Resultado del Tratamiento , Tripanocidas/administración & dosificación , Tripanocidas/farmacologíaRESUMEN
Few cases of AIDS associated to manifestations suggesting Behçet's syndrome have been reported. This case is of a young married woman who presented, during a period of 7 years, clinical manifestations consistent with the late diagnosis of Behçet's syndrome, when she developed recurrent lymphomonocytic meningoencephalitis. At this time, she was found to be infected by HIV-1. Immunosuppressive doses of glucocorticoid produced an unsatisfactory response and she evolved to death due to CNS toxoplasmosis. The latter diagnosis was presumed on the basis of magnetic resonance imaging findings and proved by necropsy after her third hospital stay. One of the factors hindering the appropriate diagnosis was the low level of CD4 and the CD4/CD8 ratio, sometimes observed in active Behçet's syndrome and higher than those observed in patients with this severe opportunistic infection. No information about the exact period of time she had been infected with HIV-1 is available. So, we do not know whether both diseases were overlooked, if the patient, infected by HIV-1, developed an unusual clinical feature consistent with Behçet's Behçet's syndrome, and subsequently evolved to AIDS.
Asunto(s)
Infecciones Oportunistas Relacionadas con el SIDA , Síndrome de Inmunodeficiencia Adquirida/complicaciones , Síndrome de Behçet/diagnóstico , Toxoplasmosis Cerebral/complicaciones , Infecciones Oportunistas Relacionadas con el SIDA/diagnóstico , Síndrome de Inmunodeficiencia Adquirida/diagnóstico , Adulto , Síndrome de Behçet/complicaciones , Diagnóstico Diferencial , Femenino , VIH-1 , Humanos , Toxoplasmosis Cerebral/diagnósticoRESUMEN
Twenty adult patients with severe infections were treated with oral ciprofloxacin, 500 or 750 mg twice daily. Treatment ranged from 8 to 25 days. Efficacy was good: 14 patients (70%) were cured, four (20%) improved and there were only two (10%) failures. Tolerance was very satisfactory, the most common side-effects being mild gastrointestinal symptoms (three patients). Only one adverse laboratory result was observed: a transient rise in blood urea nitrogen and creatinine levels. None of the adverse effects led to discontinuation of treatment. Thus, ciprofloxacin presents as a promising drug for treatment of severe infections caused by susceptible organisms when ambulatorial therapy, at least during a large part of the treatment, is possible and desirable.
Asunto(s)
Infecciones Bacterianas/tratamiento farmacológico , Ciprofloxacina/uso terapéutico , Administración Oral , Adulto , Anciano , Anciano de 80 o más Años , Bacteriemia/tratamiento farmacológico , Ciprofloxacina/efectos adversos , Femenino , Hospitalización , Humanos , Enfermedades Pulmonares/tratamiento farmacológico , Enfermedades Pulmonares/microbiología , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Estudios Prospectivos , Enfermedades de la Piel/tratamiento farmacológico , Enfermedades de la Piel/microbiología , Resultado del TratamientoRESUMEN
Seventeen adult patients with chronic osteomyelitis were treated with oral ciprofloxacin, 750 mg twice daily. Treatment ranged from 28 to 254 days. Efficacy was considered to be good, based upon clinical resolution observed in 13 patients (76%). Clinical and microbiological failure was observed in 3 patients (18%), and there was one case of reinfection. Tolerance was very satisfactory, since the adverse reactions were mild and transitory; these occurred in 7 patients (41%), being cutaneous rash in 4 patients and diarrhoea in 3 patients. No patient had to discontinue treatment. Thus, oral ciprofloxacin may be useful option for the prolonged treatment of chronic osteomyelitis, provided that it is always associated with surgical debridement. Due to the probable development of ciprofloxacin resistance in the S. aureus multiresistant strain, already observed in two patients in the present investigation, it is suggested that for the treatment of such infections another drug with antistaphylococcal activity should be associated with the ciprofloxacin.
Asunto(s)
Infecciones Bacterianas/tratamiento farmacológico , Ciprofloxacina/uso terapéutico , Osteomielitis/tratamiento farmacológico , Administración Oral , Adulto , Anciano , Anciano de 80 o más Años , Ampicilina/uso terapéutico , Enfermedad Crónica , Esquema de Medicación , Femenino , Humanos , Masculino , Persona de Mediana Edad , Resultado del TratamientoAsunto(s)
Antibacterianos/farmacocinética , Antibacterianos/química , Antibacterianos/uso terapéutico , Bacterias/metabolismo , Eritromicina/análogos & derivados , Eritromicina/química , Eritromicina/farmacocinética , Eritromicina/uso terapéutico , Humanos , Miocamicina/química , Miocamicina/farmacocinética , Miocamicina/uso terapéutico , Roxitromicina/química , Roxitromicina/farmacocinética , Roxitromicina/uso terapéuticoRESUMEN
The author analyzes the new quinolones and their use in antimicrobial therapy. He emphasizes, particularly, the similarities and differences between them, aiming to help the non-specialist to an adequate choice and correct use of these drugs of growing importance.
Asunto(s)
Antiinfecciosos/uso terapéutico , Infecciones Bacterianas/tratamiento farmacológico , 4-Quinolonas , Antiinfecciosos/administración & dosificación , Antiinfecciosos/farmacocinética , Antiinfecciosos/farmacología , Bacterias Anaerobias/efectos de los fármacosAsunto(s)
Ascaridiasis/tratamiento farmacológico , Bencimidazoles/administración & dosificación , Mebendazol/administración & dosificación , Infecciones por Nematodos/tratamiento farmacológico , Tricuriasis/tratamiento farmacológico , Humanos , Mebendazol/farmacología , Nematodos/efectos de los fármacos , Recuento de Huevos de ParásitosRESUMEN
Os autores, apresentam um caso de paciente com 14 anos de idade, portadora de tumor parotideo, submetida a tratamento cirurgico. Os exames pre-operatorios, aliados a historia clinica e dados de exame fisico, nao permitiram, com seguranca, o estabelecimento de probabilidade diagnostica.O ato cirurgico consistiu numa parotidectomia parcial (exerese do tumor e parte do lobo superficial da glandula) apos ter-se constatado, durante a inspecao, tratar-se de ganglio linfatico intra-parotideo. O exame anatomo-patologico da peca mostrou tratar-se de nodulo linfatico com arranjo nodular de celulas reticulares, sugestivo de toxoplasmose. Este diagnostico foi confirmado pelas provas sorologicas efetuadas a seguir, nao apresentando a paciente quaisquer indicios de outras manifestacoes clinicas da doenca. Os autores acreditam ser este o primeiro caso conhecido de provavel toxoplasmose aguda, de forma linfoglanular com adenopatia unica situada exclusivamente na regiao parotidea, simulando, destarte, um tumor originario desta glandula salivar maior. Apresentam, nos comentarios e comparativamente a dados da literatura mundial, a excepcionalidade de tal achado, o que justifica a presente publicacao
Asunto(s)
Adolescente , Humanos , Femenino , Neoplasias de la Parótida , ToxoplasmosisRESUMEN
Em virtude da conveniencia de procurar estipular formula para preparacao dotada de amplo espectro de atividade e destinada ao tratamento de helmintises intestinais, foi avaliada a capacidade curativa de pequenas doses unicas de mebendazol (200 mg ou 300 mg), em relacao a ascaridiase e a tricocefaliase, ja que esse composto e comumente lembrado quando sucede cogitacao de medicamento polivalente e as duas verminoses citadas afiguram-se frequentes no Brasil. Ficaram registradas as seguintes percentagens de exitos terapeuticos: ascaridiase-84,8% e 76,4%, com 200mg ou 300mg; tricocefaliase - 44,1% e 78,4%, com 200mg ou 300mg. A tolerancia ao remedio, por parte dos individuos considerados, pode ser qualificada como bastante satisfatoria convem frisar que a posologia de 300mg tornou-se viavel eliminar pouco mais de 75% das infeccoes por Ascaris lumbricoides e Trichocephalus trichiurus. Essa revelacao presta ajuda, sem duvida, aos que desejam compor, presentemente, recurso farmaceutico possuidor de respeitavel capacidade para debelar, a um so tempo, diversas verminoses concernentes ao aparelho digestivo